Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian

doi:10.1056/NEJMoa0912614

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E Clark, Andreas Hochhaus, Timothy P Hughes, Neil Gallagher, Albert Hoenekopp, Mei Dong, Ariful Haque, Richard A Larson, Hagop M Kantarjian

Research output: Contribution to journal › Original Article › peer-review

1274 Citations (Web of Science)

Original language	English
Pages (from-to)	2251-2259
Journal	NEW ENGLAND JOURNAL OF MEDICINE
Volume	362
Issue number	24
DOIs	https://doi.org/10.1056/NEJMoa0912614
Publication status	Published - 2010

Keywords

PHASE CML-CP
HARMONIZING CURRENT METHODOLOGY
CHRONIC MYELOGENOUS LEUKEMIA
PATIENTS RECEIVING IMATINIB
UP SUSTAINED SURVIVAL
BCR-ABL TRANSCRIPTS
FOLLOW-UP
PATIENTS PTS
800 MG
MOLECULAR RESPONSES

Access to Document

10.1056/NEJMoa0912614

Cite this

Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R. A., & Kantarjian, H. M. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEW ENGLAND JOURNAL OF MEDICINE , 362(24), 2251-2259. https://doi.org/10.1056/NEJMoa0912614

Saglio, Giuseppe ; Kim, Dong-Wook ; Issaragrisil, Surapol et al. / Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. In: NEW ENGLAND JOURNAL OF MEDICINE 2010 ; Vol. 362, No. 24. pp. 2251-2259.

@article{67dbdb060f79483c85f7c22a0d653803,

title = "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.",

keywords = "PHASE CML-CP, HARMONIZING CURRENT METHODOLOGY, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, UP SUSTAINED SURVIVAL, BCR-ABL TRANSCRIPTS, FOLLOW-UP, PATIENTS PTS, 800 MG, MOLECULAR RESPONSES",

author = "Giuseppe Saglio and Dong-Wook Kim and Surapol Issaragrisil and {le Coutre}, Philipp and Gabriel Etienne and Clarisse Lobo and Ricardo Pasquini and Clark, {Richard E} and Andreas Hochhaus and Hughes, {Timothy P} and Neil Gallagher and Albert Hoenekopp and Mei Dong and Ariful Haque and Larson, {Richard A} and Kantarjian, {Hagop M}",

year = "2010",

doi = "10.1056/NEJMoa0912614",

language = "English",

volume = "362",

pages = "2251--2259",

journal = "NEW ENGLAND JOURNAL OF MEDICINE ",

issn = "0028-4793",

publisher = "Massachusetts Medical Soc",

number = "24",

}

Saglio, G, Kim, D-W, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, RE, Hochhaus, A, Hughes, TP, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, RA & Kantarjian, HM 2010, 'Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.', NEW ENGLAND JOURNAL OF MEDICINE , vol. 362, no. 24, pp. 2251-2259. https://doi.org/10.1056/NEJMoa0912614

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. / Saglio, Giuseppe; Kim, Dong-Wook; Issaragrisil, Surapol et al.
In: NEW ENGLAND JOURNAL OF MEDICINE , Vol. 362, No. 24, 2010, p. 2251-2259.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

AU - Saglio, Giuseppe

AU - Kim, Dong-Wook

AU - Issaragrisil, Surapol

AU - le Coutre, Philipp

AU - Etienne, Gabriel

AU - Lobo, Clarisse

AU - Pasquini, Ricardo

AU - Clark, Richard E

AU - Hochhaus, Andreas

AU - Hughes, Timothy P

AU - Gallagher, Neil

AU - Hoenekopp, Albert

AU - Dong, Mei

AU - Haque, Ariful

AU - Larson, Richard A

AU - Kantarjian, Hagop M

PY - 2010

Y1 - 2010

KW - PHASE CML-CP

KW - HARMONIZING CURRENT METHODOLOGY

KW - CHRONIC MYELOGENOUS LEUKEMIA

KW - PATIENTS RECEIVING IMATINIB

KW - UP SUSTAINED SURVIVAL

KW - BCR-ABL TRANSCRIPTS

KW - FOLLOW-UP

KW - PATIENTS PTS

KW - 800 MG

KW - MOLECULAR RESPONSES

U2 - 10.1056/NEJMoa0912614

DO - 10.1056/NEJMoa0912614

M3 - Original Article

C2 - 20525993

SN - 0028-4793

VL - 362

SP - 2251

EP - 2259

JO - NEW ENGLAND JOURNAL OF MEDICINE

JF - NEW ENGLAND JOURNAL OF MEDICINE

IS - 24

ER -

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEW ENGLAND JOURNAL OF MEDICINE . 2010;362(24):2251-2259. doi: 10.1056/NEJMoa0912614